Mercer Global Advisors Inc. ADV Raises Holdings in DexCom, Inc. (NASDAQ:DXCM)

Mercer Global Advisors Inc. ADV raised its stake in DexCom, Inc. (NASDAQ:DXCM) by 110.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 20,345 shares of the medical device company’s stock after purchasing an additional 10,666 shares during the period. Mercer Global Advisors Inc. ADV’s holdings in DexCom were worth $1,582,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also made changes to their positions in DXCM. Nordea Investment Management AB increased its position in shares of DexCom by 2.8% in the 4th quarter. Nordea Investment Management AB now owns 80,590 shares of the medical device company’s stock valued at $6,271,000 after purchasing an additional 2,183 shares during the last quarter. First Hawaiian Bank increased its holdings in DexCom by 556.1% in the fourth quarter. First Hawaiian Bank now owns 23,159 shares of the medical device company’s stock valued at $1,801,000 after buying an additional 19,629 shares during the last quarter. Watts Gwilliam & Co. LLC acquired a new stake in DexCom in the fourth quarter valued at $3,334,000. Czech National Bank lifted its holdings in DexCom by 3.7% during the 4th quarter. Czech National Bank now owns 84,689 shares of the medical device company’s stock worth $6,586,000 after buying an additional 3,057 shares during the last quarter. Finally, Capital Investment Advisors LLC acquired a new position in shares of DexCom during the 4th quarter worth about $206,000. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently weighed in on DXCM. Wells Fargo & Company reaffirmed an “overweight” rating on shares of DexCom in a report on Saturday, March 8th. Piper Sandler lowered their target price on shares of DexCom from $100.00 to $90.00 and set an “overweight” rating for the company in a report on Friday, May 2nd. Robert W. Baird reduced their price target on shares of DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a research report on Friday, May 2nd. Redburn Atlantic raised DexCom from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $85.00 to $115.00 in a report on Monday, February 3rd. Finally, Canaccord Genuity Group lifted their target price on DexCom from $103.00 to $106.00 and gave the stock a “buy” rating in a research report on Friday, May 2nd. Five investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $98.11.

DexCom Stock Up 2.3 %

DexCom stock opened at $85.29 on Friday. The firm has a market capitalization of $33.44 billion, a price-to-earnings ratio of 59.64, a price-to-earnings-growth ratio of 2.30 and a beta of 1.43. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. DexCom, Inc. has a fifty-two week low of $57.52 and a fifty-two week high of $132.26. The stock’s fifty day moving average is $71.03 and its two-hundred day moving average is $77.09.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, May 1st. The medical device company reported $0.32 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.01). DexCom had a return on equity of 30.14% and a net margin of 14.29%. The business had revenue of $1.04 billion for the quarter, compared to analyst estimates of $1.02 billion. During the same quarter in the previous year, the firm posted $0.32 EPS. The business’s revenue was up 12.5% on a year-over-year basis. Analysts predict that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Insider Activity at DexCom

In related news, COO Jacob Steven Leach sold 14,076 shares of the firm’s stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total value of $990,668.88. Following the sale, the chief operating officer now directly owns 313,497 shares of the company’s stock, valued at approximately $22,063,918.86. This trade represents a 4.30 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Kevin R. Sayer sold 32,498 shares of the stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total transaction of $2,287,209.24. Following the transaction, the chief executive officer now directly owns 372,029 shares in the company, valued at approximately $26,183,401.02. This represents a 8.03 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 66,926 shares of company stock valued at $4,734,384. Company insiders own 0.32% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.